Expertise in
9
conditions

Dr. Anton M. Melnyk

Oncology
Texas Oncology Pharmacy-Abilene
1957 Antilley Rd, 
Abilene, TX 
Accepting New Patients
Offers Telehealth
Expertise in
9
conditions
Texas Oncology Pharmacy-Abilene
1957 Antilley Rd, 
Abilene, TX 

Overview

Anton Melnyk is an Oncologist practicing medicine in Abilene, Texas.

Dr. Melnyk is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Paget Disease of the Breast, Breast Cancer, Pleuropulmonary Blastoma, Lung Cancer, and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 9 peer reviewed articles and participating in 8 clinical trials. Dr. Melnyk is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in TX

Hospital Affiliations

Rolling Plains Memorial Hospital
Hendrick Medical Center Brownwood
Hendrick Medical Center

Languages Spoken

English
Spanish

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Baylor Scott & White Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
FirstCare
  • HMO
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Moda Health
  • EPO
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
Scott and White Health
  • HMO
  • POS
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 16 Less Insurance Carriers -

Locations

Texas Oncology Pharmacy-Abilene
1957 Antilley Rd, Abilene, TX 79606
Other Locations
Steadman Pediatrics PLLC
1665 Antilley Rd Ste 150, Abilene, TX 79606

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations
A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations
Enrollment Status: Active_not_recruiting
Publish Date: August 21, 2026
Intervention Type: Drug
Study Drugs: Tucatinib, Trastuzumab, Fulvestrant
Study Phase: Phase 2
A Phase III, Multicenter, Randomized, Double Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Canakinumab Versus Placebo as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II -IIIA and IIIB (T>5cm N2) Completely Resected (R0) Non-small Cell Lung Cancer (NSCLC)
A Phase III, Multicenter, Randomized, Double Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Canakinumab Versus Placebo as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II -IIIA and IIIB (T>5cm N2) Completely Resected (R0) Non-small Cell Lung Cancer (NSCLC)
Enrollment Status: Terminated
Publish Date: October 09, 2024
Intervention Type: Drug
Study Drug: Canakinumab
Study Phase: Phase 3
A Phase 1b/2 Study of Viagenpumatucel-L (HS-110) in Combination With Multiple Treatment Regimens in Patients With Non-Small Cell Lung Cancer (The DURGA Trial)
A Phase 1b/2 Study of Viagenpumatucel-L (HS-110) in Combination With Multiple Treatment Regimens in Patients With Non-Small Cell Lung Cancer (The DURGA Trial)
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Biological, Drug
Study Drugs: Viagenpumatucel-L, Nivolumab, Pembrolizumab, Pemetrexed
Study Phase: Phase 1/Phase 2
A Randomized Phase 2 Trial of AM0010 in Combination With Pembrolizumab vs. Pembrolizumab Alone as First-Line (1L) Therapy in Patients With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (> 50%)
A Randomized Phase 2 Trial of AM0010 in Combination With Pembrolizumab vs. Pembrolizumab Alone as First-Line (1L) Therapy in Patients With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (> 50%)
Enrollment Status: Terminated
Publish Date: January 20, 2021
Intervention Type: Drug, Biological
Study Phase: Phase 2
A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1
A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1
Enrollment Status: Terminated
Publish Date: September 11, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 2
A Single-Arm, Global, Phase 4 Study of Abemaciclib, a CDK 4 & 6 Inhibitor, in Combination With Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) in Participants With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast Cancer With Poor Prognostic Factors
A Single-Arm, Global, Phase 4 Study of Abemaciclib, a CDK 4 & 6 Inhibitor, in Combination With Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) in Participants With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast Cancer With Poor Prognostic Factors
Enrollment Status: Withdrawn
Publish Date: September 06, 2019
Intervention Type: Drug
Study Phase: Phase 4
A Pilot Study of Vigil™ Augmented Autologous Tumor Cell Immunotherapy in Combination With Pembrolizumab PD-1 Inhibitor for Patients With Advanced Melanoma
A Pilot Study of Vigil™ Augmented Autologous Tumor Cell Immunotherapy in Combination With Pembrolizumab PD-1 Inhibitor for Patients With Advanced Melanoma
Enrollment Status: Completed
Publish Date: September 27, 2017
Intervention Type: Biological, Drug
Study Phase: Phase 1
A Phase 2 Study of Vigil™ Augmented Autologous Tumor Cell Immunotherapy in Combination With Nivolumab PD-1 Inhibitor for Patients With Advanced Non-Small Cell Lung Cancer
A Phase 2 Study of Vigil™ Augmented Autologous Tumor Cell Immunotherapy in Combination With Nivolumab PD-1 Inhibitor for Patients With Advanced Non-Small Cell Lung Cancer
Enrollment Status: Withdrawn
Publish Date: July 31, 2017
Intervention Type: Biological, Drug
Study Phase: Phase 2
View 7 Less Clinical Trials

9 Total Publications

Biomarker Testing Rates and Patterns in Patients With Metastatic Non-Small Cell Lung Cancer: A Prospective, Observational Study in Community Practices.
Biomarker Testing Rates and Patterns in Patients With Metastatic Non-Small Cell Lung Cancer: A Prospective, Observational Study in Community Practices.
Journal: JCO precision oncology
Published: April 22, 2026
Similar Doctors
Expertise in
30
conditions
Dr. Jose J. Vega
Hematology | Oncology
Expertise in
30
conditions
Dr. Jose J. Vega
Hematology | Oncology
Referral may be required

Hendrick Cancer Center

2000 Pine St, 
Abilene, TX 
 (7.0 miles away)
325-670-6340
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Jose Vega is a Hematologist and an Oncologist practicing medicine in Abilene, Texas. Dr. Vega is highly rated in 30 conditions, according to our data. His clinical expertise encompasses Clear Cell Sarcoma, WT1-Related Wilms Tumor Syndromes, Pleuropulmonary Blastoma, Lung Cancer, and Gastrostomy. Dr. Vega is currently accepting new patients.

Expertise in
8
conditions
Expertise in
8
conditions
Referral may be required

Texas Oncology Pharmacy-Abilene

1957 Antilley Rd, 
Abilene, TX 
 (0.1 miles away)
325-692-0188
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Ralph Heaven is an Oncologist practicing medicine in Abilene, Texas. Dr. Heaven is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Paget Disease of the Breast, Breast Cancer, Colorectal Cancer, Bone Marrow Aspiration, and Endoscopy. Dr. Heaven is currently accepting new patients.

Expertise in
22
conditions
Dr. Mustapha A. Khalife
Hematology | Oncology
Expertise in
22
conditions
Dr. Mustapha A. Khalife
Hematology | Oncology
Referral may be required

Hendrick Cancer Center

2000 Pine St, 
Abilene, TX 
 (7.0 miles away)
325-670-6340
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Mustapha Khalife is a Hematologist and an Oncologist practicing medicine in Abilene, Texas. Dr. Khalife is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Breast Cancer, Familial Colorectal Cancer, Paget Disease of the Breast, and Lung Cancer. Dr. Khalife is currently accepting new patients.

Frequently Asked Questions about Dr. Anton M. Melnyk

How do I make an appointment with Dr. Anton M. Melnyk?

You can book an appointment with Dr. Anton M. Melnyk by calling their office at 325-692-0188. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Anton M. Melnyk a top-rated expert for Paget Disease of the Breast?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Anton M. Melnyk is classified as an Distinguished expert for Paget Disease of the Breast, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Anton M. Melnyk specialize in?

While Dr. Anton M. Melnyk is a Oncology, they have specific expertise in Paget Disease of the Breast, Breast Cancer, and Pleuropulmonary Blastoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Anton M. Melnyk participate in research or clinical trials?

Yes. Dr. Anton M. Melnyk has published 9 articles and abstracts on conditions like Paget Disease of the Breast. You can view a list of Dr. Anton M. Melnyk's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Anton M. Melnyk accept my insurance?

Dr. Anton M. Melnyk accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 325-692-0188 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Melnyk's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 96 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile